AnaMar Announces Positive Phase I Data for its Phase II Ready Compound AM1476 for Treating Fibrosis
May 23, 2023 03:00 ET
|
AnaMar AB
First-in-class, peripheral serotonin (5-HT2B) receptor antagonist being developed as a highly selective, oral, anti-fibrotic medicine for skin and lung disorders LUND, Sweden, May 23, 2023 (GLOBE...
FibroGen Reports First Quarter 2023 Financial Results
May 08, 2023 16:01 ET
|
FibroGen, Inc.
• Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into...
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
April 03, 2023 07:00 ET
|
FibroGen, Inc.
- 372 IPF Patients Enrolled -- Topline Data Anticipated Mid-2024 - SAN FRANCISCO, April 03, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the completion of patient...
FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management
November 07, 2022 16:00 ET
|
FibroGen, Inc.
Strengthens balance sheet with strategic non-dilutive capital to support strategic prioritiesSupported by global launches of EVRENZO™ in the territories partnered with Astellas Pharma Inc.FibroGen...
FibroGen to Report Third Quarter 2022 Financial Results
October 24, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close. FibroGen will also...
FibroGen to Report Second Quarter 2022 Financial Results
July 25, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also...
FibroGen to Participate at William Blair Biotech Focus Conference 2022
July 01, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William...
FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy
June 08, 2022 07:00 ET
|
FibroGen, Inc.
- 73 Ambulatory DMD Patients Enrolled -- Topline Data Anticipated 2H:2023 - SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient...
FibroGen to Present at Jefferies Healthcare Conference
May 26, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies...
FibroGen Reports First Quarter 2022 Financial Results
May 09, 2022 16:01 ET
|
FibroGen, Inc.
Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021Significant roxadustat volume growth in China in...